hemophilia A

Groundbreaking gene therapies in store for hemophiliaTreatment failures can result in a spectrum of problems for patients with hemophilia. Here’s some guidance on choosing the right therapy.
FDA Approves Emicizumab-kxwh for Hemophilia A
FDA Approves Emicizumab-kxwh for Hemophilia AEmicizumab-kxwh brings together factors IXa and X to restore the function of the missing activated factor VIII and the blood clotting process.
Treatment investigated to prevent blood-clotting disordersA new subcutaneous therapy could offer a promising solution to a bleeding disorder in both children and adults.
Bleeding disorders: When to worry, how to helpStudies have shown that 1 in 5 women who consult their doctor for heavy or prolonged bleeding during their periods actually have an underlying bleeding disorder.
New antibody eases hemophilia treatmentA new antibody eases treatment of severe hemophilia A.
FDA approves Bayer hemophilia A drugFDA recently approved antihemophilic factor VIII (recombinant) (Kovaltry, Bayer) for the treatment of hemophilia A in children and adults.
FDA OKs modified antihemophilic factor for hemophilia AFDA has approved recombinant, PEGlyated Antihemophilic Factor (Adynovate, Baxalta) for use in patients who have Hemophilia A.
FDA approves Obizur for acquired hemophilia AFDA has approved Antihemophilic Factor (Recombinant), Porcine Sequence] (Obizur, Baxter) for the treatment of bleeding episodes in adults with acquired hemophilia A.
FDA drug approvals - October 2014
FDA drug approvals - October 2014FDA actions in brief, fast-track designations, priority review.
FDA drug approvals-July 2014FDA drug approvals, priority review, breakthrough designation, fast-track designations, orphan drug designations, first-time generic approval